Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6079-6086

  Klutz, Kathrin ^a   Russ, Verena ^b   Willhauck, Michael J ^a   Wunderlich, Nathalie ^a   Zach, Christian ^a   Gildehaus, Franz Josef ^a   Göke, Burkhard ^a   Wagner, Ernst ^a,b   Ogris, Manfred ^a,b   Spitzweg, Christine ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Center of Drug Research   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER; IODINE 123; PLASMID DNA; POLYPROPYLENIMINE DENDRIMER; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER; SODIUM PERCHLORATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOISOTOPE THERAPY; SCINTILLATION CAMERA; TREATMENT RESPONSE;

ANIMALS; BIOLOGICAL AVAILABILITY; COMBINED MODALITY THERAPY; DENDRIMERS; GENE THERAPY; GENE TRANSFER TECHNIQUES; IODINE RADIOISOTOPES; MALE; MICE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; SYMPORTERS; TIME FACTORS; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 70349680762     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0851     Document Type: Article

References (46)

1. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-460 (Pubitemid 26039527)
2. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339-345 (Pubitemid 26331906)
3. Smanik PA, Ryu K-Y, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997; 138:3555-3558
4. De la Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083-1105 (Pubitemid 30452012)
5. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000;10:321-330
6. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001;86:3327-3335 (Pubitemid 32673505)
7. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol 2002;57:559-574 (Pubitemid 35316971)
8. Willhauck MJ, Samani BR, Gildehaus FJ, et al. Application of 188Re as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2007;92: 4451-4458 (Pubitemid 350074769)
9. Willhauck MJ, Samani BR, Wolf I, et al. The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:1272-1281
10. Cengic N, Baker CH, Schutz M, Goke B, Morris JC, Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2005;90:4457-4464 (Pubitemid 41159327)
11. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003;63:7840-7844 (Pubitemid 37466717)
12. Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005;12:272-280 (Pubitemid 40220629)
13. Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum Gene Ther 2007;18:916-924 (Pubitemid 47587318)
14. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001;8:1524-1531
15. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissuespecific expression of the sodium iodide symporter. Cancer Res 2000;60:6526-6530 (Pubitemid 30952162)
16. Spitzweg C, Zhang S, Bergert ER, et al. Prostate- specific antigen (PSA) promoter-driven androgen- inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999;59:2136-2141 (Pubitemid 29217677)
17. Willhauck MJ, Sharif Samani BR, Klutz K, et al. α-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008;15:214-223 (Pubitemid 351150044)
18. Dingli D, Russell SJ, Morris JC. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 2003;90:1079-1086
19. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005;12:141-161 (Pubitemid 40205096)
20. Meyer M, Wagner E. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum Gene Ther 2006;17:1062-1076 (Pubitemid 44749709)
21. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine- DNA complexes. J Gene Med 2002;4: 84-91. (Pubitemid 40277159)
22. Forrest ML, Koerber JT, Pack DW. A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem 2003;14:934-940
23. Kloeckner J, Bruzzano S, Ogris M, Wagner E. Gene carriers based on hexanediol diacrylate linked oligoethylenimine: effect of chemical structure of polymer on biological properties. Bioconjug Chem 2006;17:1339-1345 (Pubitemid 44455343)
24. Kloeckner J, Wagner E, Ogris M. Degradable gene carriers based on oligomerized polyamines. Eur J Pharm Sci 2006;29:414-425 (Pubitemid 44709863)
25. Russ V, Elfberg H, Thoma C, Kloeckner J, Ogris M, Wagner E. Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer. Gene Ther 2008;15:18-29. (Pubitemid 350269429)
26. Russ V, Gunther M, Halama A, Ogris M, Wagner E. Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. J Control Release 2008;132:131-140
27. Russ V, Wagner E. Cell and tissue targeting of nucleic acids for cancer gene therapy. Pharm Res 2007;24:1047-1057 (Pubitemid 46798888)
28. Dufes C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schatzlein AG. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 2005;65:8079-8084 (Pubitemid 41330568)
29. Weiss SJ, Philip NJ, Grollmann EF. Iodine transport in a continous line of cultured cells from rat thyroid. Endocrinology 1984;114:1090-1098
30. Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. J Clin Endocrinol Metab 2006;91:69-78. (Pubitemid 43069120)
31. Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003;24:48-77. (Pubitemid 36223279)
32. Scholz IV, Cengic N, Goke B, Morris JC, Spitzweg C. Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J Clin Endocrinol Metab 2004;89:1108-1116 (Pubitemid 38368398)
33. Spitzweg C, Scholz IV, Bergert ER, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radio-iodine in prostate cancer cells. Endocrinology 2003;144:3423-3432 (Pubitemid 36904418)
34. Dwyer RM, Schatz SM, Bergert ER, et al. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther 2005;12:835-841
35. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641-1646 (Pubitemid 38268954)
36. Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007;110:2342-2350 (Pubitemid 47523154)
37. Smrekar B, Wightman L, Wolschek MF, et al. Tissue-dependent factors affect gene delivery to tumors in vivo. Gene Ther 2003;10:1079-1088 (Pubitemid 36850230)
38. Chisholm EJ, Vassaux G,Martin-Duque P, et al. Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res 2009;69:2655-2662
39. Kircheis R, Wightman L, Schreiber A, et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther 2001;8:28-40. (Pubitemid 32162413)
40. Goula D, Benoist C, Mantero S, Merlo G, Levi G, Demeneix BA. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther 1998;5:1291-1295 (Pubitemid 28448439)
41. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207. (Pubitemid 32520323)
42. Wapnir IL, Goris M, Yudd A, et al. The Na+/Isymporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res 2004;10: 4294-4302 (Pubitemid 38878866)
43. Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002;29:13-18 (Pubitemid 34088159)
44. Petrich T, Quintanilla-Martinez L, Korkmaz Z, et al. Effective cancer therapy with the α-particle emitter [211-At]astatine in a mouse model of genetically modified sodium/iodide symporterexpressing tumors. Clin Cancer Res 2006;12:1342-1348 (Pubitemid 43342527)
45. de Bruin K, Ruthardt N, von Gersdorff K, et al. Cellular dynamics of EGF receptor-targeted synthetic viruses. Mol Ther 2007;15:1297-1305 (Pubitemid 46965326)
46. Kircheis R, Blessing T, Brunner S, Wightman L, Wagner E. Tumor targeting with surface-shielded ligand-polycation DNA complexes. J Control Release 2001;72:165-170 (Pubitemid 32522354)